Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.630
-0.020 (-1.21%)
At close: Feb 13, 2026, 4:00 PM EST
1.750
+0.120 (7.36%)
After-hours: Feb 13, 2026, 7:50 PM EST
Alzamend Neuro Employees
As of October 31, 2025, Alzamend Neuro had 7 total employees, including 4 full-time and 3 part-time employees. The number of employees did not change compared to the same quarter last year.
Employees
7
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$924,650
Market Cap
6.20M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Oct 31, 2025 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2025 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2025 | 7 | 0 | - | 4 | 3 |
| Jan 31, 2025 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2024 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2024 | 7 | 0 | - | 4 | 3 |
| Apr 30, 2024 | 7 | 0 | - | 4 | 3 |
| Jan 31, 2024 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2023 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Apr 30, 2023 | 7 | -1 | -12.50% | 4 | 3 |
| Jan 31, 2023 | 7 | 0 | - | 4 | 3 |
| Oct 31, 2022 | 7 | 0 | - | 4 | 3 |
| Jul 31, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Apr 30, 2022 | 8 | 2 | 33.33% | 4 | 4 |
| Jan 31, 2022 | 7 | 3 | 75.00% | 3 | 4 |
| Oct 31, 2021 | 7 | 3 | 75.00% | 3 | 4 |
| Jul 31, 2021 | 6 | 2 | 50.00% | 2 | 4 |
| Apr 30, 2021 | 6 | 2 | 50.00% | 2 | 4 |
| Jan 31, 2021 | 4 | 0 | - | 1 | 3 |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aptevo Therapeutics | 37 |
| Theriva Biologics | 22 |
| MetaVia | 9 |
| Purple Biotech | 9 |
| Revelation Biosciences | 9 |
| Immuron | 7 |
| Mustang Bio | 6 |
| Can-Fite BioPharma | 5 |
ALZN News
- 3 months ago - Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital - PRNewsWire
- 7 months ago - Alzamend Neuro to Present at the 2025 Military Health System Research Symposium - GlobeNewsWire
- 7 months ago - Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs - GlobeNewsWire
- 8 months ago - Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule - GlobeNewsWire
- 9 months ago - Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire
- 9 months ago - Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire
- 9 months ago - Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital - GlobeNewsWire
- 10 months ago - Alzamend Neuro Announces Reverse Stock Split - GlobeNewsWire